These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12597929)

  • 21. Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.
    Bachour DM; Chahin E; Al-Fahoum S
    Asian Pac J Cancer Prev; 2015; 16(16):7085-8. PubMed ID: 26514494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).
    Chen R; Zhou LQ; Cai XB; Xie LP; Huang YR; He DL; Gao X; Xu CL; Ding Q; Wei Q; Yin CJ; Ren SC; Wang FB; Tian Y; Sun ZQ; Fu Q; Ma LL; Zheng JH; Ye ZQ; Ye DW; Xu DF; Hou JQ; Xu KX; Yuan JL; Gao X; Liu CX; Pan TJ; Sun YH;
    Asian J Androl; 2015; 17(6):1017-21. PubMed ID: 25926603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.
    Mikolajczyk SD; Catalona WJ; Evans CL; Linton HJ; Millar LS; Marker KM; Katir D; Amirkhan A; Rittenhouse HG
    Clin Chem; 2004 Jun; 50(6):1017-25. PubMed ID: 15054080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimum PSA reflex-range.
    Benecchi L
    Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness.
    Raaijmakers R; Blijenberg BG; Finlay JA; Rittenhouse HG; Wildhagen MF; Roobol MJ; Schröder FH
    J Urol; 2004 Jun; 171(6 Pt 1):2245-9. PubMed ID: 15126795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
    Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
    Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer.
    Zhang WM; Finne P; Leinonen J; Salo J; Stenman UH
    Urology; 2000 Aug; 56(2):267-72. PubMed ID: 10925092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of serum free prostate-specific antigen level with histological findings in patients with prostatic disease.
    Lakhey M; Ghimire R; Shrestha R; Bhatta AD
    Kathmandu Univ Med J (KUMJ); 2010; 8(30):158-63. PubMed ID: 21209527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
    Nurmikko P; Pettersson K; Piironen T; Hugosson J; Lilja H
    Clin Chem; 2001 Aug; 47(8):1415-23. PubMed ID: 11468231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen complexed to alpha(1)-antichymotrypsin in the early detection of prostate cancer.
    Martínez M; España F; Royo M; Vera CD; Estellés A; Jiménez-Cruz JF; Medina P; Aznar J
    Eur Urol; 2000 Jul; 38(1):85-90. PubMed ID: 10859447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
    Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
    Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml.
    Chen R; Huang Y; Cai X; Xie L; He D; Zhou L; Xu C; Gao X; Ren S; Wang F; Ma L; Wei Q; Yin C; Tian Y; Sun Z; Fu Q; Ding Q; Zheng J; Ye Z; Ye D; Xu D; Hou J; Xu K; Yuan J; Gao X; Liu C; Pan T; Sun Y;
    PLoS One; 2015; 10(6):e0130308. PubMed ID: 26091007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial.
    Catalona WJ; Partin AW; Slawin KM; Naughton CK; Brawer MK; Flanigan RC; Richie JP; Patel A; Walsh PC; Scardino PT; Lange PH; deKernion JB; Southwick PC; Loveland KG; Parson RE; Gasior GH
    Urology; 2000 Mar; 55(3):372-6. PubMed ID: 10699613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
    Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
    Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations.
    Veltri RW; Miller MC
    Urology; 1999 Apr; 53(4):736-45. PubMed ID: 10197849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.